when is semaglutide off patent The for the key ingredient in Ozempic and Wegovy developed by Novo Nordisk set to expire in India on March 20, opening the door for a wave of low-cost Looming GLP-1 drug patent expirations

Skeletal muscle healing in sites distant from the injection location shows improvement in BPC-157-treated animal models, suggesting systemic circulation of the peptide rather than purely localized activity

It remains an investigational compound available for laboratory research only

This information should be interpreted with a qualified healthcare provider to personalize dosing, formulation choice, and adjunctive lifestyle interventions

Method: Propensity score matching (to balance differences between groups such as age, obesity, sleep apnea)

Extensively studied in growth, metabolism, tissue-repair, and GH/IGF-1 axis research

Wegovy and Zepbound are also FDA-approved specifically for chronic weight management